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The Hospital Antimicrobial Use Process: From Beginning 
to End
William R. Truong1 and Jason Yamaki2,3
1Department of Pharmacy, St. Joseph Hospital, Orange, California; 2Department of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, California; and 3Department of Pharmacy, 
Hoag Memorial Hospital Presbyterian, Newport Beach, California
Hospital antimicrobial stewardship (AMS) programs are responsible for ensuring that all antimicrobials are utilized in the most 
appropriate and safe manner to improve patient outcomes, prevent adverse drug reactions, and prevent the development of anti-
microbial resistance. This Perspectives article outlines the hospital antimicrobial use process (AUP), the foundational system that 
ensures that all antimicrobials are utilized in the most appropriate and safe manner. The AUP consists of the following steps: anti-
microbial ordering, order verification, preparation and delivery, administration, monitoring, and discharge prescribing. AMS 
programs should determine how each step contributes to how an antimicrobial is used appropriately or inappropriately at their 
institution. Through this understanding, AMS programs can integrate stewardship activities at each step to ensure that every oppor-
tunity is taken to optimize antimicrobial use during a patient’s treatment course. Hence, approaching AMS through the framework 
of a hospital’s AUP is essential to improving appropriate antimicrobial use.
Keywords. antibiotics; antimicrobial resistance; antibiotic stewardship; antimicrobial stewardship program; antimicrobial use 
process.
 Antimicrobial stewardship (AMS) is predicated on ensuring 
appropriate and optimal antimicrobial use to improve patient 
outcomes, prevent adverse drug reactions, and prevent the 
development of antimicrobial resistance [1, 2]. Although there 
is no universal definition of appropriate antimicrobial use, 
expert societies consider the “selection of the optimal anti-
microbial drug regimen including dosing, duration of therapy, 
and route of administration” as an indicator of appropriate use 
[3]. Hospital-based AMS programs are tasked with developing, 
implementing, and monitoring interventions to meet the goal of 
improving appropriate antimicrobial use. As AMS is by virtue 
an endeavor to improve pharmaceutical drug use in patients, 
stewards need to appreciate and approach AMS within the 
framework of their hospital’s antimicrobial use process (AUP) 
to comprehensively integrate effective stewardship practices. 
The AUP is the foundational system that ensures all antimicro-
bials are utilized in the most appropriate and safe manner across 
all settings. Despite being a foundational element for appropri-
ate antimicrobial usage, it may not be thoroughly reviewed as 
a whole by specifically looking at each step of the process and 
how it relates to antimicrobial usage, and how each step can be 
improved. The AUP is based broadly on the medication use pro-
cess, which traditionally consists of 5 principal steps: prescribing, 
transcribing, dispensing, administration, and monitoring [4]. 
The AUP within the context of a hospital can be adapted to 
include the following steps: antimicrobial ordering, order veri-
fication, preparation and delivery, administration, monitoring, 
and discharge prescribing (Figure  1). Optimal execution of 
each step ensures that the patient receives the right drug, at the 
right dose, at the right time, for the right duration, and with the 
narrowest spectrum of activity required to treat the infection. 
Therefore, AMS practices and processes need to be integrated at 
each of these steps to ensure this outcome. This can be achieved 
by having a holistic understanding of the antimicrobial use 
process. In this article, each step of the AUP is presented, their 
importance is explained, and examples of AMS activities are 
given that occur at each step to optimize the process.
PRESCRIBER ORDERING
Prescribing of antimicrobials during physician order entry 
is the first step of the AUP, and for this reason, it is a critical 
focus of AMS interventions as it is ideal to have the optimal 
antimicrobial entered at the beginning of the process. In hos-
pitals that utilize computerized physician order entry systems, 
electronic behavioral change interventions have been shown 
to be effective in driving appropriate antimicrobial use [5, 6]. 
Implementation of antimicrobial order sets that incorporate 
syndrome-specific clinical pathways to “guide” prescribers 
toward guideline-concordant and institutional best practice 
P E R S P E C T I V E S
Received 13 March 2018; editorial decision 23 April 2018; accepted 27 April 2018.
Correspondence: W. R. Truong, PharmD, Department of Pharmacy, St. Joseph Hospital, 1100 
West Stewart Drive, Orange, CA 92868 (william.truong2@stjoe.org).
© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases 
Society of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the work 
is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofy098
DOI: DOI: 10.1093/ofid/ofy098
Downloaded from https://academic.oup.com/ofid/article-abstract/5/6/ofy098/4989922
by Chapman University Library user
on 16 July 2018
2 • OFID • PERSPECTIVES
therapy are widely used by AMS programs to improve anti-
microbial use [7–9]. Best practice alerts (ie, “pop-ups”) utiliz-
ing clinical decision support mechanisms can be used to notify 
prescribers of which agents may or may not be appropriate 
based on computed clinical data, local susceptibilities, hospi-
tal formulary, and restriction criteria. Requiring the prescriber 
to input a clinical indication during electronic order entry has 
also been shown to be effective in reducing antimicrobial use in 
the outpatient setting and can be used in the inpatient setting 
to promote judicious use [10]. In institutions that lack robust 
electronic medical record (EMR) capabilities where best prac-
tice alerts, computerized order entry, and order sets cannot be 
utilized, hard copy best practice and institutional guidelines 
that are easily accessible can provide guidance to prescribers 
during order entry [1].
PHARMACIST ORDER VERIFICATION
An important juncture in the AUP is the step following pre-
scriber ordering: pharmacist order verification. During this 
step, the prescriber has already entered an order for a patient 
and requires verification by a pharmacist. Order verification 
pharmacists are responsible for ensuring that drug interac-
tions and allergies are assessed, dosing is adjusted for organ 
dysfunction, and duplications of therapy are reconciled. 
Many hospitals have pharmacist-driven automatic renal dos-
ing protocols that allow for timely adjustment of dosing [11]. 
Duplications in therapy (eg, double beta-lactam or double 
anaerobic coverage) ideally should be intervened on at this 
stage by contacting the prescriber to inquire about the need 
for duplication. In institutions that utilize pharmacist-driven 
pharmacokinetic dosing protocols, the pharmacist at this step 
is typically responsible for initiating the dosing and monitor-
ing of vancomycin and/or aminoglycosides to ensure attain-
ment of target serum concentrations to optimize efficacy and 
reduce toxicity [12–14]. In hospitals where preauthorization 
of restricted antimicrobials is required for ordering, order ver-
ification pharmacists ensure that each restricted agent has met 
the hospital’s policy for use [15].
PREPARATION AND DELIVERY
Once an antimicrobial order is verified and processed by the 
order verification pharmacist, pharmacy personnel are tasked 
with the preparation and compounding of each drug. Accurate 
preparation and timely delivery of the antimicrobial to the 
patient’s unit is critical for the treatment of severe infections 
manifesting in sepsis. As studies have demonstrated increas-
ing mortality when time elapses to the first administration of 
broad-spectrum antimicrobials [16, 17], pharmacy workflow 
and delivery methods need to be optimized to ensure that the 
time between drug preparation and delivery to the patient’s unit 
is reduced. Additionally, accurate preparation is necessary to 
ensure that the patient receives the correct dose and a product 
that is safe for use. The clinical ramifications of accurate and 
safe preparation are emphasized by adverse events and deaths 
that have occurred with compounded medications. According 
to Pew Charitable Trusts, during the period of 2001–2017, there 
were 1416 adverse events and 115 deaths associated with com-
pounded or repackaged medications [18]. Automated drug 
dispensing cabinets containing premixed antibiotics in patient 
care units have been shown to reduce time to intravenous anti-
biotic administration [19]. Also important is the need to edu-
cate pharmacy technicians on the importance of their role in 
the AUP and how their compounding and delivery efforts have 
an impact on patient care. Lastly, considered a “low-hanging 
fruit” intervention, antimicrobial batching during preparation 
is a method employed at this step to reduce waste and expendi-
tures for certain high-cost drugs such as daptomycin and caspo-
fungin [20].
ADMINISTRATION
Antimicrobial administration is performed by bedside nurses, 
and hence nursing serves a critical role in the AUP [21, 22]. 
Timely antimicrobial administration is a crucial factor during 
this step, and nurses should accurately record the dose and time 
of each administration. Precise administration at scheduled 
frequency intervals ensures that consistent serum drug concen-
tration levels are achieved. If cultures are ordered, every effort 
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Figure 1. Diagram of the antimicrobial use process and the possible health care professionals who are involved at each step.
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should be made to administer the antibiotics after cultures 
are taken, so long as it does not extensively prolong the time 
to antibiotic administration. This ensures optimal microbio-
logical yield of each culture, which provides critical organism 
identification and susceptibility information during the treat-
ment course. In hospitals where extended infusion beta-lactam 
administration is utilized, nurses are responsible for ensuring 
that these antibiotics are programmed to be administered at the 
correct infusion duration and that any residual antibiotic in the 
intravenous lines is infused into the patient. Furthermore, coor-
dinating the administration of vancomycin or aminoglycosides 
relative to serum level draws prevents any aberrated serum level 
results, potentially leading to suboptimal therapy. Ensuring 
compatibility of intravenous antibiotics with other drugs dur-
ing infusion is also important to maximize therapeutic effect 
and avoid adverse events.
MONITORING
Antimicrobials should be monitored for efficacy and toxicity daily. 
Certain interventions can be implemented at this stage to ensure 
that antimicrobials are appropriately managed. One interven-
tion outlined in the Centers for Disease Control and Prevention’s 
(CDC’s) Core Elements of Hospital Antibiotic Stewardship 
Programs, and now required by The Joint Commission as an 
accreditation standard, is implementation of an antibiotic time-
out. An antibiotic timeout requires the treating team to assess their 
patient’s antibiotics 48 hours after they are initiated to determine 
if they still need to be continued or if any adjustments need to be 
made [2]. After 48 hours, more diagnostic and microbiological 
data (ie, culture results) are available to guide the treating team in 
modifying antibiotics (eg, de-escalation). If technologically feas-
ible, computerized best practice alerts can be utilized to notify the 
prescriber that a timeout assessment is due and acknowledge that 
an assessment has been conducted. Institutions utilizing phar-
macist-driven timeout assessments have demonstrated improved 
antibiotic use [23, 24]. Bedside nurses, as central communicators 
throughout an inpatient stay, can also be involved in the timeout 
process by prompting the treating team to assess antimicrobials 
and duration of therapy.
A principal component of monitoring that should be per-
formed is daily prospective audit and feedback. This is con-
ducted by a clinical infectious diseases pharmacist or physician 
and is one of the core activities undertaken by an antimicrobial 
stewardship program [25–27]. Hospitals can invest in phar-
macosurveillance and data-mining software applications to 
readily identify patient cases that are candidates for steward-
ship interventions. This allows the stewardship team to review 
and provide interventions on an expanded scope of patients 
as identification of intervention opportunities is automated 
[28]. Alternatively, if these software applications are not avail-
able, manual antimicrobial reports can be generated to identify 
patient cases for stewardship interventions.
Additionally, during this stage of the AUP, patient-level 
assessments should occur through labs and physical examin-
ation to monitor for development of adverse drug reactions. For 
example, physicians and nurses should monitor for cutaneous 
reactions and/or diarrhea to determine if there are any signs of 
hypersensitivity reaction or possible Clostridium difficile infec-
tion among other medication-specific monitoring parameters. 
Furthermore, the treating and antimicrobial stewardship team 
should identify patients who are candidates for intravenous to 
oral conversion and intervene to switch the patient to oral ther-
apy [29]. The CDC recommends that hospitals have in place 
intravenous-to-oral antimicrobial conversion programs where 
conversion is done automatically, typically by a clinical pharma-
cist, when the patient meets specified inclusion and exclusion 
criteria [2]. Good communication between clinicians is critical 
in institutions that utilize rapid diagnostics. Rapid diagnostics 
are only beneficial if results are rapidly translated into appropri-
ate modifications of the patient’s antimicrobial regimen. In many 
institutions, critical culture results, whether obtained via rapid 
diagnostics or traditional culture methods, are communicated 
from the microbiology laboratory to the bedside nurse, who 
then communicates them to the physician. This process must be 
made efficient to ensure that the patient benefits from a rapid 
diagnostic result. Alternative approaches have also included 
notification directly to the team physician, as well as the patient’s 
nurse. In some institutions, results of rapid cultures are provided 
to a clinical pharmacist, who then communicates the informa-
tion to the physician with a recommendation for therapy modi-
fication [30]. The mechanism by which the physician is notified 
will depend on the resources available at the institution.
DISCHARGE PRESCRIBING
The final step in the AUP is the prescribing of antimicrobials 
for the transition from inpatient to outpatient. Once patients 
are clinically stable, they often are discharged on oral step-
down antimicrobials to complete their treatment course [31]. 
When this occurs, it is typically with an outpatient prescription, 
and at many hospitals, it may not be prescribed through the 
computerized physician order entry system. Therefore, these 
antimicrobial prescriptions may not be subjected to the stew-
ardship oversight and detailing described in the earlier AUP 
stages. This is an important gap as oral step-down therapy often 
involves a different class of antimicrobial (ie, beta-lactam to 
fluoroquinolone) or a different agent within the same class (ie, 
cefazolin to cephalexin). Hence, spectrum of activity, dosing, 
contraindications, hypersensitivity potential, and pharmacoki-
netic/pharmacodynamic properties may be different than the 
inpatient intravenous antimicrobial that a patient was receiv-
ing. This can lead to inappropriate antimicrobial prescribing at 
patient discharge [31, 32].
Discharge oral prescriptions are typically filled at outside 
pharmacies, which do not have access to the patient’s hospital 
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medical record or details on their inpatient clinical course. 
Furthermore, patients may be discharged when cultures are 
preliminary, and final results may not be available until after 
the patient leaves the hospital, potentially leaving the patient on 
inappropriate therapy (eg, resistant organism) [33]. Discharge 
prescribing is an important step in the AUP that stewardship 
programs can intervene on. Reviewing discharge prescriptions 
for appropriateness and their duration of therapy can ensure 
that the patient completes their therapy on the right drug, at the 
right dose, for the right duration, and one with the narrowest 
spectrum of activity. Hospitals can implement transition of care 
programs that consist of a coordinated team of pharmacists, 
physicians, nurses, and care coordinators to improve the patient 
discharge process. Transition of care pharmacists can be integral 
members of AMS programs by providing stewardship services 
during the discharge prescribing process as well as conducting 
medication reconciliation and reviews, and counseling patients 
on newly initiated medications. For patients being discharged 
on intravenous antibiotics, an outpatient parenteral antimicro-
bial therapy (OPAT) program can improve patient outcomes by 
reducing hospital readmissions [34].
Postdischarge antimicrobial therapy is often prolonged or 
may not be warranted at all. Thus, it is important at discharge 
planning to account for the number of days of effective anti-
microbial therapy that a patient has already received in the 
hospital to avoid excess duration of total therapy. For patients 
being discharged to a skilled nursing or long-term care facility, 
documenting the duration of therapy is critical to ensuring that 
antimicrobials are discontinued on the appropriate date [35]. In 
some cases, the patient may have completed an adequate course 
of antimicrobial therapy, and utilizing their clinical response 
and biomarkers such as procalcitonin, discontinuation of ther-
apy may be considered. This approach, particularly with the 
use of procalcitonin levels and other clinical parameters, would 
require education of clinicians, but there has been reported suc-
cess in decreasing antimicrobial use with this approach [36, 37].
CONCLUSIONS
Various AMS activities and processes may lead to positive out-
comes and occur at different steps of a continuum that can be 
termed the antimicrobial use process. Understanding all steps 
of the AUP from beginning to end will allow for institutions to 
better integrate AMS activities within the AUP. This integration 
reduces the opportunity for an inappropriate antimicrobial to be 
administered to a patient, and if administered, downstream AUP 
stewardship systems should identify and rectify the situation as 
soon as possible. Additionally, in the event that an inappropriate 
antimicrobial is administered to the patient, AMS programs can 
conduct a root cause analysis to identify the AUP stage in which 
it occurred and factors that allowed the inappropriate anti-
microbial to proceed through and reach the patient (Figure 2). 
Conducting this analysis will provide insights on how to improve 
the AUP to prevent future inappropriate antimicrobial use. By 
understanding and optimizing a hospital’s AUP, AMS programs 
can prevent or reduce inappropriate antimicrobial use.
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